We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wilmington, DE-based Incyte Corporation (INCY - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.
Incyte’s lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved for the treatment of patients with polycythemia vera (PV), patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. Incyte continues to gain traction by Jakafi’s performance. Jakafi sales are being driven by patient demand. The company is also working to expand the drug’s label.
While Jakafi sales and royalties are a key component of Incyte’s revenue growth, Iclusig sales and Olumiant royalties are also contributing to the top line. In February 2017, the European Commission approved Olumiant for patients with rheumatoid arthritis.
Incyte’s earnings track record has been decent so far. Over last four quarters, the company’s earnings surpassed expectations thrice, while missing in one. Incyte delivered an average positive earnings surprise of 67.05% in the said time frame.
Incyte Corporation Price, Consensus and EPS Surprise
Currently, Incyte has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Our consensus called for an earnings of 8 cents, while the company reported a loss of 1 cent.
Revenue: Incyte Pharma posted revenues of $382.3 million which missed our consensus estimate of $386.6 million.
Key Stats: Jakafi sales came in at $313.7 million, up 25% from a year ago. Iclusig revenues were $20.8 million, up from $13.7 million in the year-ago quarter.
Check back later for our full write up on this INCY earnings report later!
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Incyte (INCY) Reports A Loss in Q1
Wilmington, DE-based Incyte Corporation (INCY - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.
Incyte’s lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved for the treatment of patients with polycythemia vera (PV), patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. Incyte continues to gain traction by Jakafi’s performance. Jakafi sales are being driven by patient demand. The company is also working to expand the drug’s label.
While Jakafi sales and royalties are a key component of Incyte’s revenue growth, Iclusig sales and Olumiant royalties are also contributing to the top line. In February 2017, the European Commission approved Olumiant for patients with rheumatoid arthritis.
Incyte’s earnings track record has been decent so far. Over last four quarters, the company’s earnings surpassed expectations thrice, while missing in one. Incyte delivered an average positive earnings surprise of 67.05% in the said time frame.
Incyte Corporation Price, Consensus and EPS Surprise
Incyte Corporation Price, Consensus and EPS Surprise | Incyte Corporation Quote
Currently, Incyte has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Our consensus called for an earnings of 8 cents, while the company reported a loss of 1 cent.
Revenue: Incyte Pharma posted revenues of $382.3 million which missed our consensus estimate of $386.6 million.
Key Stats: Jakafi sales came in at $313.7 million, up 25% from a year ago. Iclusig revenues were $20.8 million, up from $13.7 million in the year-ago quarter.
Check back later for our full write up on this INCY earnings report later!